In hematological tumors, nivolumab has shown a low response rate in follicular lymphoma (FL) [80] and diffuse large B cell lymphoma (DLBCL) [81], but higher efficacy in classical HL [82,83], which appears to correlate positively with 9p24.1 translocation and increased PD-L1 expression [94]. This evidence concerns the gene CD274 and hematopoietic and lymphoid cell neoplasm.